Last reviewed · How we verify

optimised rituximab-schedule — Competitive Intelligence Brief

optimised rituximab-schedule (optimised rituximab-schedule) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Oncology, Immunology.

phase 3 Monoclonal antibody CD20 Oncology, Immunology Small molecule Live · refreshed every 30 min

Target snapshot

optimised rituximab-schedule (optimised rituximab-schedule) — Universität des Saarlandes. Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
optimised rituximab-schedule TARGET optimised rituximab-schedule Universität des Saarlandes phase 3 Monoclonal antibody CD20
Venetoclax; Rituximab venetoclax-rituximab Pfizer marketed BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab) BCL-2 (venetoclax); CD20 (rituximab) N/A
Columvi glofitamab Roche marketed Bispecific CD20-directed CD3 T Cell Engager [EPC] B-lymphocyte antigen CD20 2023-01-01
Lunsumio MOSUNETUZUMAB Roche marketed B-lymphocyte antigen CD20 2022-01-01
Ocrevus OCRELIZUMAB Roche marketed CD20-directed Cytolytic Antibody [EPC] B-lymphocyte antigen CD20 2017-01-01
Gazyva obinutuzumab Roche marketed CD20-directed Cytolytic Antibody [EPC] B-lymphocyte antigen CD20 2013-01-01
Kesimpta OFATUMUMAB Novartis marketed Anti-CD20 monoclonal antibody CD20 2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

  1. Pfizer · 7 drugs in this class
  2. argenx · 7 drugs in this class
  3. Johnson & Johnson · 2 drugs in this class
  4. German CLL Study Group · 2 drugs in this class
  5. Amgen · 2 drugs in this class
  6. Hoffmann-La Roche · 2 drugs in this class
  7. Brii Biosciences Limited · 2 drugs in this class
  8. Alexion Pharmaceuticals, Inc. · 2 drugs in this class
  9. Biotest · 2 drugs in this class
  10. Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). optimised rituximab-schedule — Competitive Intelligence Brief. https://druglandscape.com/ci/optimised-rituximab-schedule. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: